CureVac disappoints in COVID vaccine trial
Nature Podcast
Curvac Unmodified Vaccines
The company has said that they're going to finish the trial, because this was all based on an interm analysis of a hundred and 34 cases in a massive forty thousand person trial. In rat and monkey studies at least, it does look to be far better at eliciting antibodies. I think there's some people taking victory laps for modified arene and that that strategy has ultimately prevailed.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
